SOPHiA GENETICS SA SOPH

Company Overview

SOPHiA GENETICS SA is a Swiss-based precision medicine company that develops and commercializes cloud-based software for genomic and multimodal data analysis. The company operates at the intersection of healthcare, biotechnology, and artificial intelligence, providing clinical decision-support tools used primarily in oncology and rare disease diagnostics. Its core offering is a software-as-a-service platform that enables hospitals, laboratories, and biopharma companies to analyze complex molecular data and derive clinically actionable insights.

The company’s primary revenue is generated through recurring subscriptions and usage-based fees tied to genomic analyses performed on its platform. SOPHiA GENETICS differentiates itself through a vendor-agnostic approach to sequencing technologies, a globally federated data network, and proprietary AI-driven analytics trained on large-scale, real-world clinical datasets. The company was founded in 2011 and grew from an academic research initiative into a commercial enterprise, culminating in its public listing on the NASDAQ in 2022 under the ticker SOPH.